Press Releases

WASHINGTON—Subcommittee on National Security, the Border, and Foreign Affairs Chairman Glenn Grothman (R-Wis.) delivered opening remarks at a subcommittee hearing titled “How the Border Crisis Impacts Public Safety.” In his opening statement, Subcommittee Chairman Grothman highlighted how the failed policies from the Biden Administration have resulted in illegal aliens with criminal ...

WASHINGTON—Subcommittee on Economic Growth, Energy Policy, and Regulatory Affairs Chairman Pat Fallon (R-Texas) announced the subcommittee will hold a field hearing in Plano, Texas titled “Drilling Down: Oversight of the Challenges and Opportunities Facing U.S. Energy Production.” The hearing will examine the challenges American energy producers ...

WASHINGTON—House Committee on Oversight and Accountability Chairman James Comer (R-Ky.), Subcommittee on National Security, the Border, and Foreign Affairs Chairman Glenn Grothman (R-Wis.), and Rep. Mike Waltz (R-Fla.) are opening a probe into potential threats against critical domestic energy infrastructure after a spike in calls for violence by radical ecoterrorists on U.S. college campuses and across the globe. In a letter to FBI Director Christopher Wray, the lawmakers request a ...

WASHINGTON—House Committee on Oversight and Accountability Chairman James Comer (R-Ky.) issued the following statement on President Biden formally refusing to testify in public about his knowledge of and participation in his family’s business schemes: “The apple doesn’t fall far from the tree in the Biden family. Like his son, Hunter Biden, President Biden is refusing to testify in public about the Bidens’ corrupt influence peddling. This comes as no ...

WASHINGTON — Select Subcommittee on the Coronavirus Pandemic Chairman Brad Wenstrup (R-Ohio) will hold a hearing titled “Academic Malpractice: Examining the Relationship Between Scientific Journals, the Government, and Peer Review” to explore any potential inappropriate influence exerted by the federal government over research publications related to COVID-19. The Select Subcommittee recently obtained evidence that indicates top scientific journals Science, Nature, ...

WASHINGTON—The House Committee on Oversight and Accountability held a hearing titled “Oversight of the U.S. Food and Drug Administration.” At the hearing, lawmakers asked FDA Commissioner Robert Califf about a pattern of issues within the FDA to ensure the FDA is completing its role of regulatory oversight of the food and drug industries, prioritizing safety and ...

WASHINGTON – Today, House Committee on Oversight and Accountability Chairman James Comer (R-Ky.) is seeking information from the U.S. Department of Commerce (DOC) on its efforts to push costly, outdated, and unnecessary regulatory obstacles on the deployment and maintenance of critical internet infrastructure. In a letter to DOC Secretary Gina Raimondo, Chairman Comer outlined how the National Oceanic and Atmospheric Administration (NOAA) is pursuing an effort to impose burdensome ...

WASHINGTON—House Committee on Oversight and Accountability Chairman James Comer (R-Ky.) and Representative Mike Waltz (R-Fla.) today are raising concerns the Biden Administration’s proposed whale habitat protection rules could endanger the lives of mariners and disrupt vital economic activity. In a letter to National Oceanic and Atmospheric Administration (NOAA) Administrator Richard Spinrad, the lawmakers request a briefing to ensure the proposed standards have accounted for vessel and ...

WASHINGTON—Subcommittee on Economic Growth, Energy Policy, and Regulatory Affairs Chairman Pat Fallon (R-Texas.) today announced a hearing titled “Oversight of the Biden Administration’s Pause on Liquified Natural Gas Exports” to examine the justification and timing of the Department of Energy’s (DOE) pause on new permits for Liquified Natural Gas (LNG) ...

WASHINGTON—House Committee on Oversight and Accountability Chairman James Comer (R-Ky.) today opened a hearing titled “Oversight of the U.S. Food and Drug Administration” to bring transparency to a pattern of issues within the U.S. Food and Drug Administration (FDA) to ensure the FDA is prioritizing safety and effectiveness and incentivizing innovation.